Evidence map›Paper›PMID 27161487›Full record

ArticlePharmaceutical research2016

Controlling Release of Integral Lipid Nanoparticles Based on Osmotic Pump Technology.

Zhiqiang Tian, Qin Yu, Yunchang Xie, Fengqian Li, Yi Lu, Xiaochun Dong, Weili Zhao, Jianping Qi, Wei Wu

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhiqiang TianSchool of Pharmacy, Key Laboratory of Smart Drug Delivery of MOE and PLA, Fudan University, Shanghai, 201203, China.
Qin YuSchool of Pharmacy, Key Laboratory of Smart Drug Delivery of MOE and PLA, Fudan University, Shanghai, 201203, China.
Yunchang XieSchool of Pharmacy, Key Laboratory of Smart Drug Delivery of MOE and PLA, Fudan University, Shanghai, 201203, China.
Fengqian LiDepartment of Pharmacy, Shanghai Xuhui Dahua Hospital, Shanghai, China.
Yi LuSchool of Pharmacy, Key Laboratory of Smart Drug Delivery of MOE and PLA, Fudan University, Shanghai, 201203, China.
Xiaochun DongSchool of Pharmacy, Key Laboratory of Smart Drug Delivery of MOE and PLA, Fudan University, Shanghai, 201203, China.
Weili ZhaoSchool of Pharmacy, Key Laboratory of Smart Drug Delivery of MOE and PLA, Fudan University, Shanghai, 201203, China.
Jianping QiSchool of Pharmacy, Key Laboratory of Smart Drug Delivery of MOE and PLA, Fudan University, Shanghai, 201203, China. qijianping@fudan.edu.cn.
Wei WuSchool of Pharmacy, Key Laboratory of Smart Drug Delivery of MOE and PLA, Fudan University, Shanghai, 201203, China. wuwei@shmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo achieve controlled release of integral nanoparticles by the osmotic pump strategy using nanostructured lipid carriers (NLCs) as model nanoparticles.

methodsNLCs was prepared by a hot-homogenization method, transformed into powder by lyophilization, and formulated into osmotic pump tablets (OPTs). Release of integral NLCs was visualized by live imaging after labeling with a water-quenching fluorescent probe. Effects of formulation variables on in vitro release characteristics were evaluated by measuring the model drug fenofibrate. Pharmacokinetics were studied in beagle dogs using the core tablet and a micronized fenofibrate formulation as references.

resultsNLCs are released through the release orifices of the OPTs as integral nanoparticles. Near zero-order kinetics can be achieved by optimizing the influencing variables. After oral administration, decreased C max and steady drug levels for as long as over 24 h are observed. NLC-OPTs show an oral bioavailability of the model drug fenofibrate similar to that of the core tablets, which is about 1.75 folds that of a fast-release formulation.

conclusionControlled release of integral NLCs is achieved by the osmotic pump strategy.

Indexed as

Infusion Pumps, ImplantableAnimalsCross-Over StudiesDogsDrug Delivery SystemsFenofibrateLipidsNanoparticlesOsmotic PressureFenofibrateLipidscontrolled releasenanoparticlesnanostructured lipid carriersoral drug deliveryosmotic pump

Identifiers

PMID27161487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.